SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
SARC038: A Phase 2 Study of Regorafenib in Combination With Nivolumab in Patients With Refractory or Recurrent Osteosarcoma
Sponsor: Sarcoma Alliance for Research through Collaboration
A PHASE2 clinical study on Osteosarcoma and Osteosarcoma Metastatic, this trial is ongoing. The trial is conducted by Sarcoma Alliance for Research through Collaboration and has accumulated 17 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
17 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 12 earlier versions
-
Apr 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Oct 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sarcoma Alliance for Research through Collaboration
For direct contact, visit the study record on ClinicalTrials.gov .